Kelly C Vranas1, Jodi A Lapidus2, Linda Ganzini3, Christopher G Slatore4, Donald R Sullivan5. 1. Division of Pulmonary and Critical Care, Oregon Health & Science University, Portland, OR; Health Services Research & Development, VA Portland Health Care System, Portland, OR; Palliative and Advanced Illness Research (PAIR) Center, University of Pennsylvania, Philadelphia, PA; Section of Pulmonary and Critical Care Medicine, Veterans Affairs Portland Health Care System, Portland, OR. Electronic address: vranas@ohsu.edu. 2. Department of Biostatistics, School of Public Health, Oregon Health & Science University, Portland, OR. 3. Health Services Research & Development, VA Portland Health Care System, Portland, OR; Department of Psychiatry, Oregon Health & Science University, Portland, OR. 4. Division of Pulmonary and Critical Care, Oregon Health & Science University, Portland, OR; Health Services Research & Development, VA Portland Health Care System, Portland, OR; Knight Cancer Institute, Oregon Health & Science University, Portland, OR; Section of Pulmonary and Critical Care Medicine, Veterans Affairs Portland Health Care System, Portland, OR. 5. Division of Pulmonary and Critical Care, Oregon Health & Science University, Portland, OR; Health Services Research & Development, VA Portland Health Care System, Portland, OR; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.
Abstract
BACKGROUND: Palliative care is associated with improved survival and quality of life among patients with lung cancer; however, its influence on health-care utilization and quality of care is unclear. RESEARCH QUESTION: Is palliative care, and the setting in which it occurs, associated with health-care resource utilization and quality of care among patients with advanced lung cancer? STUDY DESIGN AND METHODS: This was a retrospective cohort study of 23,142 patients with stage IIIB/IV lung cancer in the Veterans Affairs HealthCare System between 2007 and 2013. Exposures included the receipt of specialist-delivered palliative care, and the setting of the initial palliative care encounter (inpatient or outpatient) received after cancer diagnosis. Primary outcomes included rates of ED visits, along with rates of hospitalization and odds of ICU admission within the last 30 days of life. Secondary outcomes included any health-care utilization (ED, hospital, or ICU) related to chemotherapy toxicity. We used propensity score methods to perform Poisson and logistic regression modeling. RESULTS: Among the 23,142 patients, 57% received palliative care, and 36% of initial palliative care encounters were outpatient. Compared with no palliative care, initial palliative care encounter in the outpatient setting was associated with reduced rates of ED visits (adjusted incidence rate ratio [aIRR], 0.86; 95% CI, 0.77-0.96) and hospitalizations in the last 30 days of life (aIRR, 0.64; 95% CI, 0.59-0.70). Initial palliative care encounters in both inpatient (adjusted OR [aOR], 0.63; 95% CI, 0.53-0.75) and outpatient (aOR, 0.42; 95% CI, 0.35-0.52) settings were associated with reduced odds of ICU admission in the last 30 days of life. Palliative care was also associated with reduced health-care utilization related to chemotherapy toxicity (aOR, 0.88; 95% CI, 0.82-0.95). INTERPRETATION: Palliative care (particularly in outpatient settings) is associated with reduced health-care utilization at the end of life and may improve the quality of care among patients with advanced lung cancer. These findings support the role of palliative care as an important component of comprehensive cancer care and highlight the potential benefits of outpatient palliative care services.
BACKGROUND: Palliative care is associated with improved survival and quality of life among patients with lung cancer; however, its influence on health-care utilization and quality of care is unclear. RESEARCH QUESTION: Is palliative care, and the setting in which it occurs, associated with health-care resource utilization and quality of care among patients with advanced lung cancer? STUDY DESIGN AND METHODS: This was a retrospective cohort study of 23,142 patients with stage IIIB/IV lung cancer in the Veterans Affairs HealthCare System between 2007 and 2013. Exposures included the receipt of specialist-delivered palliative care, and the setting of the initial palliative care encounter (inpatient or outpatient) received after cancer diagnosis. Primary outcomes included rates of ED visits, along with rates of hospitalization and odds of ICU admission within the last 30 days of life. Secondary outcomes included any health-care utilization (ED, hospital, or ICU) related to chemotherapy toxicity. We used propensity score methods to perform Poisson and logistic regression modeling. RESULTS: Among the 23,142 patients, 57% received palliative care, and 36% of initial palliative care encounters were outpatient. Compared with no palliative care, initial palliative care encounter in the outpatient setting was associated with reduced rates of ED visits (adjusted incidence rate ratio [aIRR], 0.86; 95% CI, 0.77-0.96) and hospitalizations in the last 30 days of life (aIRR, 0.64; 95% CI, 0.59-0.70). Initial palliative care encounters in both inpatient (adjusted OR [aOR], 0.63; 95% CI, 0.53-0.75) and outpatient (aOR, 0.42; 95% CI, 0.35-0.52) settings were associated with reduced odds of ICU admission in the last 30 days of life. Palliative care was also associated with reduced health-care utilization related to chemotherapy toxicity (aOR, 0.88; 95% CI, 0.82-0.95). INTERPRETATION: Palliative care (particularly in outpatient settings) is associated with reduced health-care utilization at the end of life and may improve the quality of care among patients with advanced lung cancer. These findings support the role of palliative care as an important component of comprehensive cancer care and highlight the potential benefits of outpatient palliative care services.
Authors: Christopher G Slatore; Laura M Cecere; Jennifer L Letourneau; Maya E O'Neil; Jonathan P Duckart; Renda Soylemez Wiener; Farhood Farjah; Colin R Cooke Journal: J Clin Oncol Date: 2012-04-02 Impact factor: 44.544
Authors: Elliott S Fisher; David E Wennberg; Thérèse A Stukel; Daniel J Gottlieb; F L Lucas; Etoile L Pinder Journal: Ann Intern Med Date: 2003-02-18 Impact factor: 25.391
Authors: Holly G Prigerson; Yuhua Bao; Manish A Shah; M Elizabeth Paulk; Thomas W LeBlanc; Bryan J Schneider; Melissa M Garrido; M Carrington Reid; David A Berlin; Kerin B Adelson; Alfred I Neugut; Paul K Maciejewski Journal: JAMA Oncol Date: 2015-09 Impact factor: 31.777
Authors: Joan M Teno; Pedro L Gozalo; Julie P W Bynum; Natalie E Leland; Susan C Miller; Nancy E Morden; Thomas Scupp; David C Goodman; Vincent Mor Journal: JAMA Date: 2013-02-06 Impact factor: 56.272
Authors: Austin Lammers; Christopher G Slatore; Erik K Fromme; Kelly C Vranas; Donald R Sullivan Journal: J Thorac Oncol Date: 2018-10-15 Impact factor: 15.609
Authors: Mahlagha Dehghan; Fatemeh Sadat Hoseini; Fatemeh Mohammadi Akbarabadi; Zahra Fooladi; Mohammad Ali Zakeri Journal: Support Care Cancer Date: 2022-08-01 Impact factor: 3.359